Cessatech (CESSA) Stock Overview
A pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CESSA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCessatech A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 17.30 |
| 52 Week High | DKK 26.00 |
| 52 Week Low | DKK 9.75 |
| Beta | 0.56 |
| 1 Month Change | -3.57% |
| 3 Month Change | -15.20% |
| 1 Year Change | 29.10% |
| 3 Year Change | 801.04% |
| 5 Year Change | 1.05% |
| Change since IPO | 47.86% |
Recent News & Updates
Shareholder Returns
| CESSA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 3.3% | 0.3% | -1.7% |
| 1Y | 29.1% | -19.8% | 10.3% |
Return vs Industry: CESSA exceeded the Swedish Pharmaceuticals industry which returned -19.8% over the past year.
Return vs Market: CESSA exceeded the Swedish Market which returned 10.3% over the past year.
Price Volatility
| CESSA volatility | |
|---|---|
| CESSA Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.8% |
Stable Share Price: CESSA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CESSA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3 | Jes Trygved | www.cessatech.com |
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development.
Cessatech A/S Fundamentals Summary
| CESSA fundamental statistics | |
|---|---|
| Market cap | DKK 321.37m |
| Earnings (TTM) | -DKK 10.90m |
| Revenue (TTM) | DKK 5.72m |
Is CESSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CESSA income statement (TTM) | |
|---|---|
| Revenue | DKK 5.72m |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 5.72m |
| Other Expenses | DKK 16.62m |
| Earnings | -DKK 10.90m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 28, 2026
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 100.00% |
| Net Profit Margin | -190.70% |
| Debt/Equity Ratio | 0% |
How did CESSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 01:11 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cessatech A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.